<?xml version="1.0" encoding="UTF-8"?>
<ref id="B122-vaccines-07-00053">
 <label>122.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Loginova</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Borisevich</surname>
    <given-names>S.V.</given-names>
   </name>
   <name>
    <surname>Maksimov</surname>
    <given-names>V.A.</given-names>
   </name>
   <name>
    <surname>Bondarev</surname>
    <given-names>V.P.</given-names>
   </name>
   <name>
    <surname>Nebolâ€™sin</surname>
    <given-names>V.E.</given-names>
   </name>
  </person-group>
  <article-title>Therapeutic efficacy of Ingavirin, a new domestic formulation against influenza A virus (H3N2)</article-title>
  <source>Antibiot Khimioter</source>
  <year>2008</year>
  <volume>53</volume>
  <fpage>27</fpage>
  <lpage>30</lpage>
  <pub-id pub-id-type="pmid">19227120</pub-id>
 </element-citation>
</ref>
